. 2020 Nov 19;124(4):797–804. doi: 10.1038/s41416-020-01169-w

Table 4.

Results of univariate and multivariate analysis of predictors for overall survival (OS) in patients with LOCRC (n = 381).

Characteristic	Categories	Univariate analysis			Multivariate analysis
Characteristic	Categories	Median OS (95% CI), mo	HR (95% CI)	P value	HR (95% CI)	P value
Sex	Male (n = 236)	75.5 (64.2–86.8)	0.70 (0.52–0.94)	0.019	0.90 (0.63–1.30)	0.591
Sex	Female (n = 145)	56.8 (43.2–70.4)	0.70 (0.52–0.94)	0.019	0.90 (0.63–1.30)	0.591
RAS status	Mutated (n = 178)	52.2 (39.0–65.4)	1.64 (1.23–2.20)	0.001	1.53 (1.13–2.05)	0.005
RAS status	Wild-type (n = 203)	78.3 (62.8–93.9)	1.64 (1.23–2.20)	0.001	1.53 (1.13–2.05)	0.005
BRAF status	Mutated (n = 4)	47.2 (4.6–89.8)	1.44 (0.35–5.85)	0.605	1.98 (0.47–8.24)	0.345
BRAF status	Wild-type (n = 293)	78.2 (68.3–88.1)	1.44 (0.35–5.85)	0.605	1.98 (0.47–8.24)	0.345
MSI status	MSI-H (n = 6)	Not reached	0.59 (0.08–4.26)	0.603	1.12 (0.12–9.74)	0.916
MSI status	MSS (n = 204)	83.2 (69.2–97.3)	0.59 (0.08–4.26)	0.603	1.12 (0.12–9.74)	0.916
Sidedness	Right (n = 109)	54.3 (47.1–61.6)	1.56 (1.15–2.12)	0.004	1.53 (1.12–2.09)	0.007
Sidedness	Left (n = 272)	76.3 (64.5–88.1)	1.56 (1.15–2.12)	0.004	1.53 (1.12–2.09)	0.007
CEA level > 10 ng/mL	Yes (n = 101)	62.6 (52.7–72.5)	1.22 (0.88–1.69)	0.215	1.19 (0.86–1.66)	0.286
CEA level > 10 ng/mL	No (n = 271)	74.6 (64.2–84.9)	1.22 (0.88–1.69)	0.215	1.19 (0.86–1.66)	0.286
≥2 liver lesions	Yes (n = 180)	63.5 (49.8–77.1)	1.18 (0.88–1.57)	0.256	1.01 (0.71–1.44)	0.937
≥2 liver lesions	No (n = 192)	78.2 (66.6–89.9)	1.18 (0.88–1.57)	0.256	1.01 (0.71–1.44)	0.937
pCR	Yes (n = 10)	93.6 (0.0–∞)	0.58 (0.21–1.58)	0.291	0.80 (0.25–2.58)	0.713
pCR	No (n = 269)	64.9 (51.7–78.1)	0.58 (0.21–1.58)	0.291	0.80 (0.25–2.58)	0.713
Margin	Positive (n = 56)	62.6 (47.7–77.5)	1.15 (0.75–1.74)	0.509	1.02 (0.56–1.86)	0.944
Margin	Negative (n = 324)	72.1 (61.9–82.3)	1.15 (0.75–1.74)	0.509	1.02 (0.56–1.86)	0.944
Extrahepatic disease	Yes (n = 52)	45.1 (33.3–56.9)	1.57 (1.07–2.32)	0.021	1.52 (1.03–2.25)	0.033
Extrahepatic disease	No (n = 329)	72.1 (62.3–82.0)	1.57 (1.07–2.32)	0.021	1.52 (1.03–2.25)	0.033
Postoperative therapy	Yes (n = 260)	78.2 (66.7–89.7)	0.64 (0.47–0.86)	0.004	0.66 (0.48–0.89)	0.008
Postoperative therapy	No (n = 119)	56.8 (46.1–67.5)	0.64 (0.47–0.86)	0.004	0.66 (0.48–0.89)	0.008

CEA carcinoembryonic antigen, HR hazard ratio, MSI microsatellite instability, MSI-H high-frequency MSI, MSS microsatellite stable, pCR pathologic complete response.

p < 0.05 was considered statistically significant.